RA
NVCR icon

Rise Advisors’s NovoCure NVCR Stock Holding History

Rise Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-30
Closed -$469 – 1182
2024
Q3 		$469 Hold
30
– – ﹤0.01% 1195
2024
Q2 		$514 Hold
30
– – ﹤0.01% 1192
2024
Q1 		$469 Hold
30
– – ﹤0.01% 1217
2023
Q4 		$448 Hold
30
– – ﹤0.01% 569
2023
Q3 		$485 Sell
30
-25
-45% -$721 ﹤0.01% 582
2023
Q2 		$2.28K Hold
55
– – ﹤0.01% 502
2023
Q1 		$3.31K Hold
55
– – ﹤0.01% 509
2022
Q4 		$4.03K Hold
55
– – ﹤0.01% 474
2022
Q3 		$4K Sell
55
-50
-48% -$3.9K ﹤0.01% 471
2022
Q2 		$7K Hold
105
– – 0.01% 401
2022
Q1 		$9K Buy
105
+30
+40% +$2.21K 0.01% 348
2021
Q4 		$5.63K Buy
+75
New +$7.53K 0.01% 394

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Rise Advisors's NVCR Position: Q4 2024 in Review

Rise Advisors sold out of NovoCure (NVCR) in Q4 2024, closing a stake of 30 shares — an estimated $469 sold.

Rise Advisors first reported a position in NVCR in Q4 2021 and held it in 12 quarters. The position peaked at $9K in Q1 2022. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2024.

  • Rise Advisors reported no remaining NovoCure position as of Q4 2024 after selling out during the quarter.
  • Rise Advisors sold 30 NovoCure shares in Q4 2024, an estimated $469.
  • Rise Advisors first reported a position in NovoCure in Q4 2021 and held it in 12 quarters.
  • Rise Advisors's NovoCure position peaked at $9K in Q1 2022.
  • 238 funds tracked by Wall St. Rank held NovoCure as of Q4 2024.

Based on Rise Advisors's 13F filing for Q4 2024, filed 7 Jan 2025.